Gyros platform integrated into second, US-based, contract research organization


Radix BioSolutions adopts Gyrolab xP workstation for immunoassay development

Gyros AB, a leader in the automation of miniaturized immunoassays, confirmed today that Radix BioSolutions, a US-based contract research organization specializing in custom assay development, reagent manufacturing, and a provider of assay services, will integrate a Gyrolab™ xP workstation into their immunoassay development programs. Kerry Oliver, CEO at Radix Biosolutions explained the reasoning behind the decision, “The Gyros™ platform enables us to develop immunoassays more rapidly than any other approaches currently available. At Radix we differentiate ourselves by fostering strong relationships with our customers by meeting project requirements and timelines, and always striving to exceed expectations. Our scientists provide the experience and capabilities in reagent definition and production, robust assay development and validation, and the regulatory compliance required during the development of a customer’s therapeutic. It is essential for us to leverage leading edge technology at each stage of a project in order to best fulfill the unique needs of each customer.”

Erik Walldén, CEO at Gyros, added: “We are extremely pleased that Radix BioSolutions have recognized one of the key benefits of our immunoassay platform, namely rapid assay development. We also believe that their unique approach of making identified assay reagents commercially available will enable other Gyrolab xP workstation users working in GLP environments in the USA to procure quality controlled reagents from Radix for their own laboratory needs.”

For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: /

Notes to editors:
About Gyros (

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.